The CRL means that the FDA is not satisfied with RVNC’s reply to the 483 deficiencies. After meeting with the FDA to obtain additional feedback (as stated in today’s PR), RVNC will have to fix the remaining problems and resubmit the BLA, which will start a 6-month clock for the FDA to render a decision.
Market Data 
Markets 
AI
